Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NUDT1 | P36639 | 1/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.54 |
| ▸ | HPGD | P15428 | 1/20 | 0.54 |
| ▸ | MEN1 | O00255 | 4/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.51 |
| ▸ | MAPT | P10636 | 3/20 | 0.51 |
| ▸ | HTT | P42858 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 2/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | GALR3 | O60755 | 1/20 | 0.50 |
| ▸ | NR2F2 | P24468 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
| ▸ | CCNE2 | O96020 | 3/20 | 0.49 |
| ▸ | CCNE1 | P24864 | 3/20 | 0.49 |
| ▸ | CDK2 | P24941 | 3/20 | 0.49 |
| ▸ | CDK4 | P11802 | 2/20 | 0.49 |
| ▸ | CCND1 | P24385 | 2/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23645086 | 0.79 | PRNP (0.55) | KDM4ESMN1; SMN2ALDH1A1HPGDMEN1 | |
| SCHEMBL11712509 | 0.78 | KDM4E (0.65) | KDM4ESMN1; SMN2ALDH1A1HPGDMEN1 | |
| SCHEMBL31098995 | 0.78 | KDM4E (0.65) | KDM4ESMN1; SMN2ALDH1A1HPGDMEN1 | |
| SCHEMBL8698747 | 0.77 | KDM4E (0.52) | KDM4ESMN1; SMN2ALDH1A1HPGDMEN1 | |
| SCHEMBL9314099 | 0.75 | KDM4E (0.66) | KDM4ESMN1; SMN2ALDH1A1HPGDMEN1 | |
| SCHEMBL3056940 | 0.75 | MEN1 (0.51) | MEN1KMT2AMAPTHTTCYP1A2 | |
| SCHEMBL1577669 | 0.75 | ALDH1A1 (0.63) | KDM4ESMN1; SMN2ALDH1A1HPGDMEN1 | |
| SCHEMBL8691756 | 0.74 | KDM4E (0.56) | KDM4ESMN1; SMN2ALDH1A1HPGDMEN1 | |
| SCHEMBL17560838 | 0.73 | NUDT1 (0.88) | NUDT1CYP1A2GAA | |
| SCHEMBL20878223 | 0.73 | NUDT1 (0.88) | NUDT1CYP1A2GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7250510-B2 | Transition metal complexes of N-heterocyclic carbenes, method of preparation and use in transition metal catalyzed organic transformations | TOTAL SYNTHESIS, LTD. (CA) | 2007-07-31 | — | — | US | disclosed |
| US-7250510-B2 | Transition metal complexes of N-heterocyclic carbenes, method of preparation and use in transition metal catalyzed organic transformations | TOTAL SYNTHESIS, LTD. (CA) | 2007-07-31 | — | — | US | disclosed |
| US-20070073055-A1 | Transition metal complexes of N-heterocyclic carbenes, method of preparation and use in transition metal catalyzed organic transformations | TOTAL SYNTHESIS, LTD. (CA) | 2007-03-29 | — | — | US | disclosed |
| US-20070073055-A1 | Transition metal complexes of N-heterocyclic carbenes, method of preparation and use in transition metal catalyzed organic transformations | TOTAL SYNTHESIS, LTD. (CA) | 2007-03-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070073055-A1 | Transition metal complexes of N-heterocyclic carbenes, method of preparation and use in transition metal catalyzed organic transformations | NDC1, NBAS, NUDC | NUDT1 46/4885KDM4E 3358/4885SMN1; SMN2 2928/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.